Presentation is loading. Please wait.

Presentation is loading. Please wait.

How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?  Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,

Published byBrenda Whitehead Modified over 5 years ago

Similar presentations

Presentation on theme: "How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?  Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,"— Presentation transcript:

1 How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed? 
Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD, Shunzo Hatooka, MD, Yasushi Yatabe, MD, Tetsuya Mitsudomi  Journal of Thoracic Oncology  Volume 8, Issue 3, Pages (March 2013) DOI: /JTO.0b013e31827e2435 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Computed tomography images of two representative pulmonary nodules with GGO. A, A part solid (1%–25 %) GGO lesion became larger and increased the solid component (26%–50 %) after 3.3 years. B, However, a pure GGO lesion had persisted without changing in size for 6.3 years. GCO, ground-glass opacity. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 The changes in size of the 108 evaluated lesions, (A) from the time of the first presentation to the last computed tomography examination. B, Some of the 69 lesions that were 1 cm or less in size became larger, (C), some of the 82 pure GGO lesions also grew in size during the observation period. GCO, ground-glass opacity. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 The changes in size of all 29 lesions that grew. The changes in size between CT examinations were measured to analyze each lesion's tendency to grow. The first changes in size are shown with highly colored lines and subsequent changes are shown with light-colored lines. All 29 lesions began to grow within the first 3 years of observation. CT, computed tomography. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31827e2435) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?  Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for Growth  Miyako Hiramatsu, MD, Takuya Inagaki,

Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for Growth  Miyako Hiramatsu, MD, Takuya Inagaki,
Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201  Hisao Asamura, MD, Tomoyuki.

Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201  Hisao Asamura, MD, Tomoyuki.
Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.
Difficulties in Diagnosis and Management of Ectopic Cushing Syndrome

Difficulties in Diagnosis and Management of Ectopic Cushing Syndrome
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
The Moth-Eaten Lung Journal of Thoracic Oncology

The Moth-Eaten Lung Journal of Thoracic Oncology

Similar presentations

Ads by Google